Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.55M, compared with -$17.3M a year earlier. Trailing-twelve-month EBITDA was -$74.74M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$40.06M (+45.5%) for the fiscal year ending Dec 2026, a step up from the -302.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.55M+7.2% QoQ
- Last fiscal yearDec 2025
- -$73.49M-302.9% YoY
- LTMMar 2026
- -$74.74M-18129.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.2% | — | — |
| 1 year | -302.9% | +45.5% | +348.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (73.49M) USD
- Year-over-year change
- -302.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (73.49M) | -302.9% |
| FY2024 | 2024-12-31 | (18.24M) | +80.8% |
| FY2023 | 2023-12-31 | (95.16M) | +13.3% |
| FY2022 | 2022-12-31 | (109.72M) | -40.1% |
| FY2021 | 2021-12-31 | (78.33M) | — |
EBITDA vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 EBITDA of -$74.74M is the 6th highest of the 10 companies compared; the peer median is -$67.05M.
- Its year-over-year change of -18129.5% is the lowest of 10, against a peer median of -0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $92.9M | +159.9% | — | 939.0% | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$43.15M | -177.1% | — | 291.9% | |
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$74.74M | -18129.5% | — | — | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
| LTM Mar 2026 | -$211.5M | -0.8% | — | 333.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| Peer median (excluding FULC) | -$67.05M | -0.8% | — | 312.5% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.